Epilepsy is one of the world’s most prevalent neurological diseases, affecting 50 million people globally [1]. Epilepsy significantly impairs patients’ quality of life (QOL). Previous studies of the QOL of patients with epilepsy (PWE) have focused primarily on higher-income countries; one systematic review found only 25 of 86 studies on QOLIE characterized populations outside of Europe or North America [1]. Despite this focus in the literature on higher income countries, approximately 80% of PWE reside in low and middle income countries (LMICs), where epilepsy presents a higher burden of disease [2].
16
JUL
JUL
0